Avmapki-Fakzynja Combination: A Breakthrough in Treating Low-Grade Serous Ovarian Cancer
DOI:
https://doi.org/10.63501/zedbyg98Abstract
Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of epithelial ovarian
cancer characterized by unique molecular features and poor response to conventional
chemotherapy. Recent advances in molecular profiling have led to the development of
targeted therapies, including MEK and FAK inhibitors. On May 8, 2025, the FDA
approved AVMAPKI™ FAKZYNJA™ CO-PACK, a combination of avutometinib and
defactinib, specifically for adults with KRAS-mutated recurrent LGSOC who have
undergone prior systemic therapy. This dual inhibitor regimen targets the MAPK and
FAK signaling pathways, showing promising efficacy with an overall response rate of
44% in clinical trials. While offering a novel and more effective treatment option, the
therapy requires careful monitoring for potential side effects such as liver toxicity and
skin reactions. This approval marks a significant advancement in personalized
treatment for LGSOC and highlights the need for improved accessibility to ensure
patient benefit.
References
References
1. Manning-Geist BL, Cantor T, O’Cearbhaill RE, Grisham RN. Redefining the standard of
care for low-grade serous ovarian cancer. Clin Adv Hematol Oncol. 2024 Jun;22(5):205–
26.
2. Elsherif S, Javadi S, Viswanathan C, Faria S, Bhosale P. Low-grade epithelial ovarian
cancer: what a radiologist should know. Br J Radiol. 2019 Mar;92(1095):20180571.
3. Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, et al. Lowgrade serous ovarian cancer: expert consensus report on the state of the science. Int J
Gynecol Cancer. 2023 Sep 4;33(9):1331–44.
4. Gonzalez A, Nagel CI, Haight PJ. Targeted Therapies in Low-Grade Serous Ovarian
Cancers. Curr Treat Options Oncol. 2024 Jul;25(7):854–68.
5. Verastem, Inc. FDA approves Avutometinib (AvmapkiTM) and Defactinib (FakzynjaTM)
combination therapy – first-ever approval of a RAF/MEK and FAK inhibitor regimen
[Internet]. Needham (MA): Verastem, Inc.; 2024 May 29 [cited 2025 May 27]. Available
6. University of Chicago Medicine. Low-grade epithelial ovarian cancers [Internet].
Chicago (IL): University of Chicago Medicine; [date unknown] [cited 2025 May 27].
Available from: https://www.uchicagomedicine.org/cancer/types-treatments/ovariancancer/low-grade-epithelial-ovarian-cancers.
7. Wang Q, Cao SH, Li YY, Zhang JB, Yang XH, Zhang B. Advances in precision therapy
of low-grade serous ovarian cancer: A review. Medicine. 2024 Apr 26; 103(17):e34306.
8. National Cancer Institute. Avutometinib - NCI Drug Dictionary [Internet]. Bethesda
(MD): National Cancer Institute; [date unknown] [cited 2025 May 27]. Available from:
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib.
9. Hu HH, Wang SQ, Shang HL, Lv HF, Chen BB, Gao SG, et al. Roles and inhibitors of
FAK in cancer: current advances and future directions. Front Pharmacol. 2024;
15:1274209.
10. WebMD. Avmapki Fakzynja Co-Pack (avutometinib and defactinib): Uses, Side Effects,
Interactions, Pictures, Warnings & Dosing [Internet]. WebMD; 2025 [cited 2025 May
27]. Available from: https://www.webmd.com/drugs/2/drug-501673/avmapki-fakzynjaco-pack-avutometinib-and-defactinib/details.
11. Cancer Therapy Advisor. Avmapki plus Fakzynja granted accelerated approval for
ovarian cancer [Internet]. New York (NY): Haymarket Media, Inc.; 2024 May 29 [cited
2025 May 27]. Available from: https://www.cancertherapyadvisor.com/news/avmapkiplus-fakzynja-granted-accelerated-approval-for-ovarian-cancer/ .
12. Hendrikse CSE, Theelen PMM, van der Ploeg P, Westgeest HM, Boere IA, Thijs AMJ, et
al. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in
ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2023 Apr;
171:83–94.
13. Agha RA, Mathew G, Rashid R, Kerwan A, Al-Jabir A, Sohrabi C, Franchi T, Nicola M,
Agha M. Transparency In The reporting of Artificial INtelligence – the TITAN guideline.
Premier Journal of Science 2025:10;100082.
Downloads
Published
Issue
Section
License
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given to the author(s) and the source. To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0